Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more
Lipum AB (LIPUM) - Total Liabilities
Latest total liabilities as of December 2025: Skr11.63 Million SEK
Based on the latest financial reports, Lipum AB (LIPUM) has total liabilities worth Skr11.63 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lipum AB - Total Liabilities Trend (2017–2025)
This chart illustrates how Lipum AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lipum AB Competitors by Total Liabilities
The table below lists competitors of Lipum AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
Germany | €16.70 Billion |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
USA | $38.21 Million |
|
Equites Property Fund Ltd
JSE:EQU
|
South Africa | ZAC12.99 Billion |
|
Nureca Limited
NSE:NURECA
|
India | ₹259.46 Million |
|
Noble Helium Ltd
AU:NHE
|
Australia | AU$11.07 Million |
|
Levinstein Eng
TA:LEVI
|
Israel | ILA2.18 Billion |
|
Noble Finance Company
PINK:NBLWF
|
USA | $2.98 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Lipum AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipum AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipum AB (2017–2025)
The table below shows the annual total liabilities of Lipum AB from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr11.63 Million | -50.55% |
| 2024-12-31 | Skr23.51 Million | +211.91% |
| 2023-12-31 | Skr7.54 Million | +15.90% |
| 2022-12-31 | Skr6.50 Million | -70.14% |
| 2021-12-31 | Skr21.78 Million | +217.46% |
| 2020-12-31 | Skr6.86 Million | +309.56% |
| 2019-12-31 | Skr1.68 Million | -81.31% |
| 2018-12-31 | Skr8.96 Million | +1944.11% |
| 2017-12-31 | Skr438.40K | -- |